Capricor Therapeutics Inc (NASDAQ:CAPR) Short Interest Update

Capricor Therapeutics Inc (NASDAQ:CAPR) was the recipient of a large growth in short interest in the month of November. As of November 30th, there was short interest totalling 4,410,000 shares, a growth of 14.5% from the November 15th total of 3,850,000 shares. Based on an average daily trading volume, of 3,430,000 shares, the short-interest ratio is currently 1.3 days.

Insiders Place Their Bets

In related news, major shareholder Shinyaku Co Ltd Nippon acquired 2,798,507 shares of the business’s stock in a transaction on Friday, September 20th. The stock was purchased at an average cost of $5.36 per share, for a total transaction of $14,999,997.52. Following the completion of the transaction, the insider now directly owns 7,090,351 shares of the company’s stock, valued at approximately $38,004,281.36. The trade was a 65.21 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 12.00% of the company’s stock.

Institutional Trading of Capricor Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Main Street Financial Solutions LLC grew its stake in shares of Capricor Therapeutics by 37.5% in the second quarter. Main Street Financial Solutions LLC now owns 27,500 shares of the biotechnology company’s stock worth $131,000 after acquiring an additional 7,500 shares during the period. SG Americas Securities LLC purchased a new position in Capricor Therapeutics in the 3rd quarter worth $133,000. Bank of New York Mellon Corp boosted its stake in shares of Capricor Therapeutics by 12.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 79,782 shares of the biotechnology company’s stock worth $381,000 after acquiring an additional 9,040 shares in the last quarter. The Manufacturers Life Insurance Company purchased a new stake in shares of Capricor Therapeutics during the third quarter worth $161,000. Finally, Sassicaia Capital Advisers LLC acquired a new position in Capricor Therapeutics during the 3rd quarter worth $192,000. Institutional investors and hedge funds own 21.68% of the company’s stock.

Capricor Therapeutics Stock Up 4.7 %

Shares of CAPR traded up $0.62 during trading hours on Monday, reaching $13.88. The company’s stock had a trading volume of 1,231,165 shares, compared to its average volume of 1,181,694. The company has a 50 day moving average of $18.42 and a two-hundred day moving average of $10.07. Capricor Therapeutics has a 1-year low of $3.52 and a 1-year high of $23.40. The firm has a market cap of $631.12 million, a price-to-earnings ratio of -13.58 and a beta of 3.98.

Analyst Upgrades and Downgrades

Several research firms have recently commented on CAPR. Piper Sandler began coverage on shares of Capricor Therapeutics in a research report on Monday, October 21st. They set an “overweight” rating and a $35.00 target price for the company. Oppenheimer reiterated an “outperform” rating and issued a $15.00 price objective on shares of Capricor Therapeutics in a report on Monday, September 23rd. Maxim Group lifted their price objective on Capricor Therapeutics from $12.00 to $25.00 and gave the company a “buy” rating in a research report on Wednesday, September 25th. Cantor Fitzgerald lifted their price target on shares of Capricor Therapeutics from $25.00 to $30.00 and gave the stock an “overweight” rating in a research note on Thursday, November 14th. Finally, HC Wainwright reissued a “buy” rating and issued a $77.00 price objective on shares of Capricor Therapeutics in a research note on Thursday, November 14th. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $34.50.

Capricor Therapeutics Company Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.